D2V Clinical

?? Inspirational Stories: Every person with diabetes has a story of resilience and strength. This month, we celebrate those stories. If you or someone you love is living with diabetes, know that your journey inspires countless others.? #NationalDiabetesMonth #Inspiration

?? To the caregivers, family members, and friends supporting loved ones with diabetes: Your role is invaluable. This November, we honor your dedication and the love you show every day. Thank you for being a crucial part of the diabetes community. #ThankYouCaregivers #SupportMatters

November marks National Diabetes Month, a dedicated time to raise awareness and unite in support of those impacted by diabetes. At D2V Clinical, we recognize the significance of ongoing research, innovation, and unwavering support to enhance the lives of individuals managing diabetes. Diabetes requires strength, resilience, and access to effective care. This month, we honor the courage of those living with diabetes and recommit ourselves to advancing scientific research that drives meaningful change. Every step taken in understanding, treating, and preventing diabetes matters. Let’s use this opportunity to learn more, uplift each other, and advocate for continuous progress in diabetes care and research. Together, we can inspire hope and create a healthier future for all. #NationalDiabetesMonth #DiabetesAwareness #D2VClinical #ResearchMatters

We are thrilled to announce an opening for a ???Contract Associate Clinical Project Manager!??? If you're looking to kickstart your career in project management within the clinical research field, this entry-level role is your gateway to success. If you're ready to take the next step in your career and make a meaningful impact in clinical research, we want to hear from you! ?? Share or tag someone who might be interested! ?? #JobOpportunity?| #ClinicalTrials?| #ProjectManagement?| #CareerGrowth?| #JoinUs?

**Press Release: Ruiinno Therapeutics Receives IND Clearance for MDI-1228 Mesylate Gel to Enter Phase II Clinical Trial for Chronic Diabetic Foot Ulcers** ? North Carolina, USA, September 19, 2024 – Ruiinno Therapeutics, a joint venture between Myinno Biopharma and D2V Clinical, is proud to announce that its novel drug candidate, MDI-1228 mesylate gel, has received 30-day Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to officially advance into Phase II clinical trials. The drug candidate, a differentiated Janus Kinase (JAK) inhibitor, will focus on treating chronic non-healing diabetic foot ulcers, a condition with limited treatment options. ? This clearance marks a significant milestone in the development of MDI-1228 mesylate gel, building on the successful completion of a Phase I study in China. Ruiinno Therapeutics, officially registered in May 2024, has been strategically positioning itself for commercial success by selecting high-impact, differentiated indications. Since its inception, teams from both Myinno Biopharma and D2V Clinical have been working diligently to lay a strong foundation for Ruiinno’s future, ensuring the company is well-prepared for expansion into the U.S. market. Ruiinno’s submission to the FDA also highlights the company’s dedication to rigorous scientific inquiry and collaboration. After multiple rounds of comprehensive discussions with the FDA, Ruiinno provided compelling data and scientific rationale, resulting in the timely IND clearance for this Phase II trial. The upcoming clinical trial represents a key step forward for Ruiinno Therapeutics as it continues to develop innovative treatments for unmet medical needs in the biopharmaceutical industry. Stay tuned for further updates as Ruiinno Therapeutics embarks on this exciting new chapter. #RuiinnoTherapeutics #D2VClinical #MyinnoBiopharma #JAKInhibitor #FDAApproval #Biopharma #ClinicalTrials #DiabeticFootUlcers #INDClearance #PharmaInnovation #HealthTech

Gabriela Ortiz we are inspired by your post about Megan Bannon! ?? Her journey through such a challenging battle is nothing short of remarkable, and it's incredible to see her transform that experience into a powerful narrative through her book.?She is lucky to have you as a friend. Megan’s resilience and determination are a beautiful reminder that our toughest challenges can become the foundation for growth and inspiration. Her story will undoubtedly touch many lives and encourage others to embrace their own struggles with hope and courage. Here’s to celebrating her achievements and the new chapter she’s embarking on! Keep shining, Megan! You are truly a beacon of strength and creativity. ????? #Inspiration #Resilience #Survivor #Author

Drug Formulation Development: Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery https://lnkd.in/ecHzT5t8 AI leading the way of more advancements in these complex platforms.

Phase 1 Clinical Trials: Asgard Therapeutics' study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108 https://lnkd.in/e2cmPEKK

BioPharma + Innovation: The Center for Immunology Science and Immunology Diagnostics Announce a Major Breakthrough Discovery: DNA-Based Proof of the Disease of Fibromyalgia https://lnkd.in/eSAsQigH Excited to share this research finding.

Phase 1 Clinical Trials: First patient dosed with ADC therapy designed to disrupt tumor blood supply https://lnkd.in/e5JSkJHA Great innovation in ADCs.